{"id":1893,"date":"2020-03-04T03:59:24","date_gmt":"2020-03-04T03:59:24","guid":{"rendered":"https:\/\/sbiprod.wpengine.com\/?page_id=1893"},"modified":"2026-01-19T15:37:45","modified_gmt":"2026-01-19T06:37:45","slug":"news","status":"publish","type":"page","link":"https:\/\/www.sbipharma.co.jp\/en\/news\/","title":{"rendered":"News"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"1893\" class=\"elementor elementor-1893\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-bc64b1e animated-fast elementor-section-boxed elementor-section-height-default elementor-section-height-default elementor-invisible\" data-id=\"bc64b1e\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;,&quot;background_background&quot;:&quot;slideshow&quot;,&quot;background_slideshow_gallery&quot;:[{&quot;id&quot;:2496,&quot;url&quot;:&quot;https:\\\/\\\/www.sbipharma.co.jp\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/SBI_NewsTop-PC-1.jpg&quot;}],&quot;background_slideshow_loop&quot;:&quot;yes&quot;,&quot;background_slideshow_slide_duration&quot;:5000,&quot;background_slideshow_slide_transition&quot;:&quot;fade&quot;,&quot;background_slideshow_transition_duration&quot;:500}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b030ab2\" data-id=\"b030ab2\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-458bbc9 elementor-widget elementor-widget-heading\" data-id=\"458bbc9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">News<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-200d33c8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"200d33c8\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-368dd610 cust-news-list\" data-id=\"368dd610\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4d56e67c sbi-tabs elementor-tabs-view-horizontal elementor-widget elementor-widget-tabs\" data-id=\"4d56e67c\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"newslist\" data-widget_type=\"tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-tabs\">\n\t\t\t<div class=\"elementor-tabs-wrapper\" role=\"tablist\" >\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1291\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1291\" aria-expanded=\"false\">2026<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1292\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1292\" aria-expanded=\"false\">2025<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1293\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1293\" aria-expanded=\"false\">2024<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1294\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1294\" aria-expanded=\"false\">2023<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1295\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1295\" aria-expanded=\"false\">2022<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1296\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1296\" aria-expanded=\"false\">2021<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1297\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1297\" aria-expanded=\"false\">Before 2020<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<div class=\"elementor-tabs-content-wrapper\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1291\" aria-expanded=\"false\">2026<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1291\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1291\" tabindex=\"0\" hidden=\"false\"><p>\t\t<div data-elementor-type=\"page\" data-elementor-id=\"2948\" class=\"elementor elementor-2948 elementor-2564 elementor-2564\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7fdea635 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7fdea635\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-17e4952f\" data-id=\"17e4952f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1292\" aria-expanded=\"false\">2025<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1292\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1292\" tabindex=\"0\" hidden=\"hidden\"><p>\t\t<div data-elementor-type=\"section\" data-elementor-id=\"1896\" class=\"elementor elementor-1896\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7d087791 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7d087791\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-43fdc67d\" data-id=\"43fdc67d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-55014b63 elementor-grid-1 elementor-grid-tablet-2 elementor-grid-mobile-1 elementor-widget elementor-widget-newslist\" data-id=\"55014b63\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;columns&quot;:&quot;1&quot;,&quot;item_ratio&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;row_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:40,&quot;sizes&quot;:[]},&quot;columns_tablet&quot;:&quot;2&quot;,&quot;columns_mobile&quot;:&quot;1&quot;,&quot;item_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"newslist.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sbi-filters-bar  filter-label-active\">\r\n          <div class=\"sbi-filters-label\"> Category<\/div>\r\n    \t\t<ul class=\"elementor-portfolio__filters\">\r\n\t\t\t<li class=\"elementor-portfolio__filter elementor-active\" data-filter=\"__all\">All<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"27\">Information<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"28\">News<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\r\n    <\/div>\r\n\t\t\t\t<div class=\"elementor-portfolio elementor-grid elementor-posts-container\">\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-13282 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2025.11.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice of Initiation and First Patient Enrollment in Phase III Study in Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer\u3000(ASTROPIC study)\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., announces initiation of Phase III clinical study (ASTROPIC study) and first patient enrollment evaluating 5-ALA during ovarian cancer debulking surgery <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20251121en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-13156 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2025.10.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnounces Publication of a Research Paper on 5-ALA from Tokyo University of Science in &#8220;Life&#8221;, the effects of 5-ALA on anti-fatigue in mice.\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. and Tokyo University of Science announce the publication of a research article entitled \u201cAntifatigue Effects of 5-Aminolevulinic Acid Chronic Treatment on Mice\u201d in an international scientific journal, Life. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20251021en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-12766 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2025.07.29 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of Publication of Research Paper on Investigator-Initiated Clinical Trial of 5-ALA Hydrochloride and SFC for Pediatric Mitochondrial Disease\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> Announcement of Publication of Research Paper on Investigator-Initiated Clinical Trial of 5-ALA Hydrochloride and SFC for Pediatric Mitochondrial Disease <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20250729en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-12582 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2025.05.29 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPublication on UroToday of Results from Domestic Phase III Study (SPP2C102) Aimed at Administration Modification of ALAGLIO\u00ae Divided Granules 1.5g and ALAGLIO\u00ae Oral 1.5g\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> Publication on UroToday of Results from Domestic Phase III Study (SPP2C102) Aimed at Administration Modification of ALAGLIO\u00ae Divided Granules 1.5g and ALAGLIO\u00ae Oral 1.5g <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20250529_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1293\" aria-expanded=\"false\">2024<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1293\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1293\" tabindex=\"0\" hidden=\"hidden\"><p>\t\t<div data-elementor-type=\"page\" data-elementor-id=\"2950\" class=\"elementor elementor-2950 elementor-2566 elementor-2566\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2cce8ee0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2cce8ee0\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fd18d1b\" data-id=\"fd18d1b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-51b923a2 elementor-grid-1 elementor-grid-tablet-2 elementor-grid-mobile-1 elementor-widget elementor-widget-newslist\" data-id=\"51b923a2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;columns&quot;:&quot;1&quot;,&quot;item_ratio&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;row_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:40,&quot;sizes&quot;:[]},&quot;columns_tablet&quot;:&quot;2&quot;,&quot;columns_mobile&quot;:&quot;1&quot;,&quot;item_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"newslist.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sbi-filters-bar  filter-label-active\">\r\n          <div class=\"sbi-filters-label\"> Category<\/div>\r\n    \t\t<ul class=\"elementor-portfolio__filters\">\r\n\t\t\t<li class=\"elementor-portfolio__filter elementor-active\" data-filter=\"__all\">All<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"28\">News<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\r\n    <\/div>\r\n\t\t\t\t<div class=\"elementor-portfolio elementor-grid elementor-posts-container\">\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-11493 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2024.11.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnounces Publication of a Research Paper on 5-ALA from Kumamoto University in Cell -5-ALA may prevent neurodegeneration in Parkinson&#8217;s disease and other synucleinopathies-\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. announces the publication of a research article entitled \u201cRNA G-quadruplexes form scaffolds that promote neuropathological \u03b1-synuclein aggregation\u201d from the Institute of Molecular Embryology and Genetics (IMEG), Kumamoto University, in an international scientific journal, Cell. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/202411127_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-10709 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2024.09.25 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharma to succeed Marketing Authorization of \u201cAlabel\u00ae Oral 1.5g\u201d from Nobelpharma\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. will succeed marketing authorization of \u201cAlabel\u00ae Oral 1.5g\u201d in Japan from Nobelpharma Co., Ltd. as of October 1st, 2024. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20240925_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-9988 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2024.05.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice of company profile download page\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> You can download the company profile in PDF format. (Japanese only) New: Download <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20240521\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-9483 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2024.01.31 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals and TAGCyx ANNOUNCES A MILESTONE ACHIEVEMENT OF THE RESEARCH AND\u3000DEVELOPMENT COLLABORATION OF INNOVATIVE CANCER THERAPY\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. and TAGCyx Biotechnologies Inc. hereby announces that a progress has been made in the research and development collaboration to develop innovative products in the field of cancer treatment carried out by the two companies. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20240131en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1294\" aria-expanded=\"false\">2023<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1294\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1294\" tabindex=\"0\" hidden=\"hidden\"><p>\t\t<div data-elementor-type=\"section\" data-elementor-id=\"5705\" class=\"elementor elementor-5705\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-36224cde elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"36224cde\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4b2893f8\" data-id=\"4b2893f8\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-735f07d6 elementor-grid-1 elementor-grid-tablet-2 elementor-grid-mobile-1 elementor-widget elementor-widget-newslist\" data-id=\"735f07d6\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;columns&quot;:&quot;1&quot;,&quot;item_ratio&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;row_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:40,&quot;sizes&quot;:[]},&quot;columns_tablet&quot;:&quot;2&quot;,&quot;columns_mobile&quot;:&quot;1&quot;,&quot;item_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"newslist.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sbi-filters-bar  filter-label-active\">\r\n          <div class=\"sbi-filters-label\"> Category<\/div>\r\n    \t\t<ul class=\"elementor-portfolio__filters\">\r\n\t\t\t<li class=\"elementor-portfolio__filter elementor-active\" data-filter=\"__all\">All<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"34\">Group company news<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"28\">News<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\r\n    <\/div>\r\n\t\t\t\t<div class=\"elementor-portfolio elementor-grid elementor-posts-container\">\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-8556 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2023.11.28 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharma and Scivita Medical entered into exclusive distribution agreement of single use endoscopes in urology field in Japan\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharma and Scivita Medical have officially signed an exclusive distributorship agreement for Scivita\u2019s Single-Use Urology Videoscope, including single-use ureteroscope and disposable cystoscope in Japan. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20231128_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-7585 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2023.08.17 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPublication of a Research Paper -5-ALA+SFC might improve symptoms of Electron Transfer Complex I deficiency in Drosophila-\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. and Graduate School of Science, Tokyo Metropolitan University hereby announce the publication of a research article entitled &#8220;5-Aminolevulinic acid bypasses mitochondrial complex I deficiency and corrects physiological dysfunctions in Drosophila &#8221; in an international academic journal, Human Molecular Genetics. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20230817_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-7185 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2023.07.26 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnounces Publication of Research Paper on 5-ALA phosphate for Sarcopenia\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., provided 5-ALA phosphate and ferrous citrate (SFC) to Juntendo University Graduate School and the specified clinical trial for Sarcopenia (principal investigators: Hirotaka Watada and Yoshifumi Tamura) was conducted. The article entitled &#8220;Efficacy and Safety of 5-ALA and SFC on Skeletal Muscle Index and Physical Function in Patients with Sarcopenia: A Multicenter, Double-Blind, Randomized, Controlled Trial (ALADDIN Study)&#8221; was published in the international scientific journal &#8220;Nutrients&#8221;. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20230726_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-6087 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2023.05.29 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice regarding US FDA Medical Device Registration of \u201cAladuck 405\/II\u201d\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals announces today that the medical light source device &#8220;Aladuck405\/II&#8221; marketed in Japan has been registered as a class II medical device with the U.S. FDA (Food and Drug Administration). <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20230529_en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-34 post-6010 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Group company news<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2023.05.12 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNutraIngredients-Awards granted for clinical study project with the food supplement 5-ALA + SFC as an immune system enhancer for COVID-19 vaccines<br><font size=\"3\">(SBI Holdings, photonamic)<\/font>\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> A press release has been announced by SBI Holdings. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/group-company-news-en\/20230512en\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-34 post-5510 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Group company news<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2023.02.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPhotonamic and Lumeda Enter into Collaboration for a Clinical Study with Photodynamic Therapy (\u201cPDT\u201d) in the Field of Non-Small Cell Lung Cancer (NSCLC)<br><font size=\"3\">(SBI Holdings, photonamic)<\/font>\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> A press release has been announced by SBI Holdings. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/group-company-news-en\/20230220\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1295\" aria-expanded=\"false\">2022<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1295\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1295\" tabindex=\"0\" hidden=\"hidden\"><p>\t\t<div data-elementor-type=\"section\" data-elementor-id=\"5092\" class=\"elementor elementor-5092\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-c26bd0e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"c26bd0e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-17aeb36c\" data-id=\"17aeb36c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2cd5597d elementor-grid-1 elementor-grid-tablet-2 elementor-grid-mobile-1 elementor-widget elementor-widget-newslist\" data-id=\"2cd5597d\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;columns&quot;:&quot;1&quot;,&quot;item_ratio&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;row_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:40,&quot;sizes&quot;:[]},&quot;columns_tablet&quot;:&quot;2&quot;,&quot;columns_mobile&quot;:&quot;1&quot;,&quot;item_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"newslist.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sbi-filters-bar  filter-label-active\">\r\n          <div class=\"sbi-filters-label\"> Category<\/div>\r\n    \t\t<ul class=\"elementor-portfolio__filters\">\r\n\t\t\t<li class=\"elementor-portfolio__filter elementor-active\" data-filter=\"__all\">All<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"28\">News<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\r\n    <\/div>\r\n\t\t\t\t<div class=\"elementor-portfolio elementor-grid elementor-posts-container\">\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-4941 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2022.12.16 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice regarding Succession of Supplement Business to SBI ALApromo\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals etc. using 5-aminolevulinic acid (\u201c5-ALA\u201d) has resolved today at the Board of Directors meeting to succeed its supplement business, a part of the business, by way of absorption-type company split to SBI ALApromo Co., Ltd., setting February 21, 2023 (plan) as the effective date. After this absorption-type company split, SBI ALApromo will be in charge of all the supplement business-related business. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20221215\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1296\" aria-expanded=\"false\">2021<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1296\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"6\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1296\" tabindex=\"0\" hidden=\"hidden\"><p>\t\t<div data-elementor-type=\"section\" data-elementor-id=\"3596\" class=\"elementor elementor-3596\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-480b5c93 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"480b5c93\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-588a0126\" data-id=\"588a0126\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-33b3a109 elementor-grid-1 elementor-grid-tablet-2 elementor-grid-mobile-1 elementor-widget elementor-widget-newslist\" data-id=\"33b3a109\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;columns&quot;:&quot;1&quot;,&quot;item_ratio&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;row_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:40,&quot;sizes&quot;:[]},&quot;columns_tablet&quot;:&quot;2&quot;,&quot;columns_mobile&quot;:&quot;1&quot;,&quot;item_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"newslist.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sbi-filters-bar  filter-label-active\">\r\n          <div class=\"sbi-filters-label\"> Category<\/div>\r\n    \t\t<ul class=\"elementor-portfolio__filters\">\r\n\t\t\t<li class=\"elementor-portfolio__filter elementor-active\" data-filter=\"__all\">All<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"34\">Group company news<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"28\">News<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\r\n    <\/div>\r\n\t\t\t\t<div class=\"elementor-portfolio elementor-grid elementor-posts-container\">\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-4048 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2021.12.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPublication of a Research Paper on 5-ALA from Tokyo Metropolitan University  in FEBS Open Bio  -5-ALA\/SFC extend healthspan in Drosophila-\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> \u3000SBI Pharmaceuticals Co., Ltd., Graduate School of Science, Tokyo Metropolitan University and Department of Neurogenetics, National Center for Geriatrics and Gerontology hereby announce the publication of a research article entitled &#8220;5- aminolevulinic acid and sodium ferrous citrate improves muscle aging and extend healthspan in Drosophila&#8221; in an international academic journal, FEBS Open Bio. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20211227\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-34 post-4024 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Group company news<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2021.10.13 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tResults of A First-in-Human Study for New Application of Photodynamic Therapy with 5-Aminolevulinic Acid for Extracorporeal Photopheresis Published in \u201cPharmaceutics\u201d<br><font size=\"3\">(SBI Holdings, photonamic)<\/font>\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> A press release has been announced by SBI Holdings. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/group-company-news-en\/20211013\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3721 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2021.03.08 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tStart of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., and the University of Oxford in the United Kingdom hereby announce that the University of Oxford has \u00a0initiated a dose-finding Phase II clinical trial [Pre-operative 5-Aminolevulinic acid to activate haem oxygenase to improve outcomes in cardiac surgery: A dose finding study] to develop a cardioprotective agent combining 5-ALA hydrochloride and Sodium ferrous citrate for the mitigation of ischemia-reperfusion injury in response to cardiac surgery under cardiopulmonary bypass under the terms of the clinical trial sponsorship agreement between the two parties. The first patient has been dosed at the John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20210308\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3664 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2021.03.01 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNew Release of \u201cAladuck 405\u201d, Bicolor LED Medical Light Source\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> \u00a0 SBI Pharmaceuticals. Co., Ltd., subsidiary company of SBI Holdings, Inc. is a company researching and developing pharmaceuticals, supplements, cosmetics and medical devices utilizing 5-aminolevulinic acid. We would like to announce that SBIP has released a new product today, \u201cAladuck 405\u201d, a medical light source device. \u00a0 <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20210301\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1297\" aria-expanded=\"false\">Before 2020<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1297\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"7\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1297\" tabindex=\"0\" hidden=\"hidden\"><p>\t\t<div data-elementor-type=\"page\" data-elementor-id=\"2951\" class=\"elementor elementor-2951\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-37b6afd elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"37b6afd\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-84556b1\" data-id=\"84556b1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5c0dc9c elementor-grid-1 elementor-grid-tablet-2 elementor-grid-mobile-1 elementor-widget elementor-widget-newslist\" data-id=\"5c0dc9c\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;columns&quot;:&quot;1&quot;,&quot;item_ratio&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;row_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:40,&quot;sizes&quot;:[]},&quot;columns_tablet&quot;:&quot;2&quot;,&quot;columns_mobile&quot;:&quot;1&quot;,&quot;item_gap&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"newslist.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sbi-filters-bar  filter-label-active\">\r\n          <div class=\"sbi-filters-label\"> Category<\/div>\r\n    \t\t<ul class=\"elementor-portfolio__filters\">\r\n\t\t\t<li class=\"elementor-portfolio__filter elementor-active\" data-filter=\"__all\">All<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"27\">Information<\/li>\r\n\t\t\t\t\t\t\t<li class=\"elementor-portfolio__filter\" data-filter=\"28\">News<\/li>\r\n\t\t\t\t\t<\/ul>\r\n\r\n    <\/div>\r\n\t\t\t\t<div class=\"elementor-portfolio elementor-grid elementor-posts-container\">\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3556 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2020.11.25 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., Tokyo, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research and develop collaboration to develop innovative products in the field of cancer treatment. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/sbi-pharmaceuticals-and-tagcyx-announces-the-research-and-development-collaboration-of-inovative-cancer-therapy\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-2280 news type-news status-publish has-post-thumbnail hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2019.08.09 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tA Collaboration Research Related to Development of Mitochondrial Disease Treatment by 5-Aminolevulinic Acid and Sodium Ferrous Citrate was Published\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. Saitama Medical University Chiba Children&#8217;s Hospital Juntendo University SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director, President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., Saitama Medical University, Chiba Children&#8217;s Hospital and Juntendo University published a result from a collaboration study on Scientific Reports, of Nature Publishing Group. Mitochondrial [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20190802\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-2281 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2019.06.18 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tThe collaboration study with Cancer Chemotherapy Center of JFCR was published in Scientific Reports, an online journal of Nature\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director, President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japan Foundation for Cancer Research (Laboratory: Tokyo; Division Head: Shingo Dan) announce that the outcome from the mutual collaboration study was just published in Scientific Reports, an online journal of Nature. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20190618\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3227 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2018.03.30 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tComprehensive Commercialization Rights Granted to Neopharma on the Pharmaceuticals Containing 5-ALA\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &#038; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1, hereby announces that SBI Pharmaceuticals has granted the comprehensive commercialization rights on the pharmaceuticals containing 5-ALA including \u201cALAGLIO Divided Granules 1.5g\u201d in the territory of MENA *2 and India to neopharma Japan Co., Ltd. (Head office: Chiyoda-ku, Tokyo; Representative Director: Satofumi Kawata; \u201cneopharma Japan\u201d), a subsidiary of neopharma LLC *3, a company of the United Arab Emirates (UAE) engaged in production and marketing of pharmaceuticals. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20180330\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3228 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2018.01.25 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPresentation of Research Paper on 5-ALA by Yamagata University, Faculty of Medicine to PLOS ONE, a U.S. Scientific Journal ~ 5-ALA Deficiency Attenuates Mitochondrial Function and Impairs Glucose Tolerance~\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. Yamagata University, Faculty of Medicine SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &amp; President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in the research and development of pharmaceuticals, health foods and cosmetics using 5-ALA (5-Aminolevulinic acid) (*1) and Yamagata University, Faculty of Medicine (Campus: Yamagata-shi, Yamagata; [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20180125\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3229 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2017.12.18 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tLaunch of the Photodynamic Diagnostic Agent \u201cALAGLIO\u00ae Divided Granules 1.5g\u201d  -Contributing to the Initial Treatment of Non-Muscle Invasive Bladder Cancer through the Visualization of Tumor Lesions &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> Chugai Pharmaceutical Co., Ltd. SBI Pharmaceuticals Co., Ltd. TOKYO, December 18, 2017 &#8212; Chugai Pharmaceutical Co., Ltd. (Head office: Tokyo; Chairman &amp; CEO: Osamu Nagayama; \u201cChugai\u201d) announced that it will launch the photodynamic diagnostic agent, \u201cALAGLIO\u00ae Divided Granules 1.5g\u201d (\u201cthis Agent\u201d) on December 19th. This Agent was developed by SBI Pharmaceuticals Co., Ltd., (Head office: [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20171218\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3231 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2017.09.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\t\u201cALAGLIO\u00ae Divided Granules 1.5g,\u201d a Photodynamic Diagnostic Agent Obtained Manufacture and Marketing Approval\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &#038; President: Yoshitaka Kitao; \u201cSBI Pharma\u201d), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA (5-Aminolevulinic acid) (*1) and Chugai Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Tokyo; Chairman &#038; CEO: Osamu Nagayama; \u201cChugai\u201d) hereby announce that the manufacture and marketing approval of a photodynamic diagnostic agent, \u201cALAGLIO\u00ae Divided Granules 1.5g\u201d (Generic name: Aminolevulinic acid hydrochloride; \u201cthis Agent\u201d) has been obtained from the Ministry of Health, Labour and Welfare for the indication of diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20170927\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3232 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2017.04.24 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPositive Data of Phase III Clinical Trial in Patients of Non-Muscle Invasive Bladder Cancer were Presented at the 105th Annual Meeting of the Japanese Urological Association\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &amp; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)(*1), hereby announces that the resection of bladder cancer by using aminolevulinic acid hydrochloride (SPP-005) [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20170424\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3234 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2017.03.13 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharma and Chugai Enter an Agreement of Exclusive Marketing Rights for \u201cALAGLIO\u00ae Granule 1.5g\u201d in Japan\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. Chugai Pharmaceutical Co., Ltd. TOKYO, March 13, 2017 &#8212; SBI Pharmaceuticals Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and President: Yoshitaka Kitao; \u201cSBI Pharma\u201d), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA* (5-Aminolevulinic acid), has entered a licensing agreement with Chugai Pharmaceutical [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20170313\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3235 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2017.01.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on the Start of Phase II Clinical Trial using 5-ALA by University of Oxford and SBI Pharmaceuticals\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. University of Oxford SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &amp; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1 and the University of Oxford in the United [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20170127\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3236 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.10.26 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tExclusive License Agreement Concluded with Neopharma on the Therapeutic Drug s for Diabetes and Malaria Infection\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &amp; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1, hereby announces that SBI Pharmaceuticals has concluded the exclusive license agreement with Neopharma LLC. [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20161026\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3238 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.09.26 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tResearch Paper on the Safety and Usefulness of 5-ALA in the Patients with Type 2 Diabetes in Bahrain in the Food Intervention Test Published in the \u201cJournal of Diabetes Research\u201d\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director &amp; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1, hereby announces that the research paper on the safety and usefulness [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160926\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3241 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.07.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a U. S. Patent for Treatment of Influenza Virus Infection  through Joint Application with Tokushima University\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d), hereby announces that a patent has recently been registered in the United States of America for the treatment of influenza virus infection. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160720\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3240 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.07.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a U. S. Patent on the External Preparation for Skin Containing 5-ALA\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*, hereby announces that a patent has recently been registered in the United States of America on the [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160720a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3253 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.05.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Enhancer of Survival of Transplanted Organ through Joint Application with National Center for Child Health and Development\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*, hereby announces that a patent has recently been registered in Japan for an agent [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160520\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3252 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.05.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Treatment and Prevention of Radiation Damage through Joint Application with The University of Tokyo\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d) (*1), hereby announces that a patent has recently been registered in Japan for the [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160520a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3258 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.05.18 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Treatment and Prevention of Influenza Virus Infection through Joint Application with Tokushima University\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d) (*1), hereby announces that a patent has recently been registered in Japan for the [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160518\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3260 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.03.16 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent on a Device to Identify Cancer Metastasis in Sentinel Lymph Node\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d) is a subsidiary of SBI Holdings, Inc. that engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d) *1, hereby announces that a patent has recently been registered in Japan [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160316\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3261 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.03.15 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Photodynamic Therapy Using a Photosensitizer or 5-Aminolevulinic Acids\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA)*, hereby announces that a patent has recently been registered in Japan for a photodynamic [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160315\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3266 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.03.14 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Treatment and Prevention of Cancer Anemia\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*, hereby announces that a patent has recently been registered in Japan for the treatment [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160314a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3265 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.03.14 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Treatment and Prevention of Chronic Kidney Disease\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1, hereby announces that a patent has recently been registered in Japan for the treatment [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160314b\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3263 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2016.03.14 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a Patent for Photodynamic Diagnosis and Photobleaching-Prevention Agent through Joint Application with Tokyo Institute of Technology\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1, hereby announces that a patent has recently been registered in Japan for a photodynamic [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20160314c\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3268 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.10.22 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tCurative and Protective Effects of the Combined Treatment of 5-aminolevulinic Acid and Iron against Malaria Infection was Confirmed in Animal Model.\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d) (*1) announced in Antimicrobial Agents and Chemotherapy published on October 21 [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20151022\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3267 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.10.22 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRegistration of a U. S. Patent on a Method  for Treating Diabetes Containing 5-ALA as an Active Ingredient\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1. We are pleased to inform you that a U. S. Patent [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20151022a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3269 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.09.04 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tProduct Registration of Food Supplement in Jordan\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*. We are pleased to inform that SBI Pharmaceuticals has received from [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150904\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3270 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.06.08 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tReproCELL and SBI Pharmaceuticals Develop Selective Removal Technology of Residual iPS Cells from iPS Derived-differentiated Cells for Regenerative Medicine Through Technological Application of SBI Pharmaceuticals\u2019 5-ALA\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. ReproCELL Inc. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)* and ReproCELL Inc. (Head office: Kohoku-ku, Yokohama, Kanagawa; Chief [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150608\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3272 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.05.07 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAcquisition of a Patent through Joint Application with National Hospital Organization for Therapeutic Agent for Allergic Rhinitis Containing 5-ALA as an Active Ingredient\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*. We are pleased to inform you that SBI Pharmaceuticals has obtained [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150507\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3275 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.02.05 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRelease of Medical Light Source &#8220;Violet LD Light Source Alcedo LS-VSD&#8221;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*. We are pleased to announce the launch of our new product, [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150205\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3276 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.01.19 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAcquisition of a Patent through Joint Application with Tokyo Institute of Technology\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*. We are pleased to inform you that we at SBI Pharmaceuticals [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150119\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3277 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.01.16 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tConclusion of a Patent Licensing Agreement with Cosmo Oil\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods, cosmetics and medical devices for diagnosis using 5-aminolevulinic acid (\u201c5-ALA\u201d)*. We are pleased to inform you that [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150116\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3278 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2015.01.14 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAcquisition of a Patent for Prophylactic\/Ameliorating Agent for Adult Diseases Containing 5-ALA as an Active Ingredient\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1. We are pleased to inform you that SBI Pharmaceuticals has obtained [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20150114\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3279 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.08.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPresentation of Research Paper on 5-ALA by Osaka City University  to PLOS ONE, a U.S. Scientific Journal  \u2014 Findings of ALA-PDT in killing MRSA, one of the major bacterial species causing  in-hospital infections \u2014\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. Osaka City University SBI\u00a0 Pharmaceuticals\u00a0 Co.,\u00a0 Ltd.\u00a0 (Head\u00a0 office:\u00a0 Minato-ku,\u00a0 Tokyo;\u00a0 Representative\u00a0 Director\u00a0 and\u00a0 CEO:Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140821\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3280 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.07.30 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tConclusion of Agreement on Joint Research between the University of Oxford in the United Kingdom and SBI Pharmaceuticals  \u2014 Planning to start a phase II clinical trial to assess the effectiveness of 5-ALA in preventing a  reduction in cardiac output after heart bypass surgery \u2014\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. Oxford University SBI Pharmaceuticals and the University of Oxford in the United Kingdom have signed an agreement for joint research to start a phase II clinical trial to assess the effectiveness of 5-aminolevulinic acid (\u201c5-ALA\u201d) (*1) in preventing a reduction in cardiac output (*2) after heart bypass surgery. [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140730\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3282 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.05.29 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tProposal on Development of Green Light Source is Selected for NEDO\u2019s \u201cFY2013 Innovation Commercialization Venture Support Project\u201d\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d) is a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBIH\u201d) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140529\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3283 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.04.22 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Officers to Serve as Visiting Professors at Fudan University in China\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d) is a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBIH\u201d) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140422\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3287 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.04.01 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tRelease of Medical Light Source \u201cBicolor LED Light Source Aladuck LS-DLED\u201d\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1. SBI Pharmaceuticals will begin selling the bicolor medical LED light [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20140401\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3288 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.03.28 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice Regarding Start of Clinical Studies on Type 2 Diabetes by Using 5-ALA at the Bahrain Defense Force Royal Medical Service Hospital\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d) is a subsidiary of SBI Holdings, Inc. engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1). It has been engaging in the 5-aminolevulinic acid (\u201c5-ALA\u201d) [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140328\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3289 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.03.17 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tReproCELL and SBI Pharmaceuticals Agree on a Joint Research  Regarding ES\/iPS Cell Technology Using 5-ALA\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. ReproCELL Inc. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1 and ReproCELL Inc. (Head office: Kohoku-ku, Yokohama, Kanagawa; Chief [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20140317\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3290 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.02.03 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of Communication to Grant a Patent in Europe for Therapeutic Agent for Male Sterility through Administration of 5-Aminolevulinic Acid\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1. We are pleased to announce that the European Patent Office [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140203\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3291 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.01.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of Decision to Grant a Patent in Japan for Method of Detecting Bladder Cancer through Oral Administration of 5-Aminolevulinic Acid\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d)*1. We are pleased to announce that we have been received [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140121\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3292 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2014.01.16 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of the First Successful Surgical Removal of Bladder Cancer in the Middle East Using 5-Aminolevulinic Acid as an Intraoperative Diagnostic Drug at a Medical Center of Arabian Gulf University in Bahrain\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. The SBI Group is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d) at SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. We are pleased to inform you [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20140116\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3293 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.12.18 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tPresentation of Research Paper on 5-ALA by Kochi University to PLoS ONE, a U.S. Scientific Journal  \u2014 Findings of 5-Aminolevulinic Acid (5-ALA) in Protecting against  Cisplatin-Induced Acute Kidney Injury (AKI) \u2014\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. The SBI Group is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d) at SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc. (SBIH). We are pleased to inform [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20131218\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3294 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.12.03 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tFindings of Mechanism of 5-aminolevulinic Acid (5-ALA) and Iron in Synergistically Inhibiting Growth of Plasmodium Falciparum Malaria Parasites\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> The University of Tokyo Tokyo Institute of Technology MRC National Institute for Medical Research SBI Pharmaceuticals Co., Ltd. The University of Tokyo, a national university (main campus: Bunkyo-ku, Tokyo; President: Junichi Hamada), Tokyo Institute of Technology, a national university (main campus: Meguro-ku, Tokyo; President: Yoshinao Mishima),MRC National Institute for Medical Research (London, U.K. Director: Jim [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20131203\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3295 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.09.26 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNew Launch of \u201cALAGLIO\u00ae Internal Medicine 1.5g,\u201d an Orally-administered in vivo Diagnostic Agent for Malignant Glioma\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We\u00a0 are\u00a0 pleased\u00a0\u00a0 to\u00a0 inform\u00a0 you\u00a0 that\u00a0 SBI\u00a0 Pharmaceuticals\u00a0\u00a0 Co.,\u00a0 Ltd.\u00a0 (Head\u00a0 office:\u00a0 Minato-ku,\u00a0\u00a0 Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that today [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130926\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3296 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.09.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Obtains a Business License for Selling and Renting Highly Controlled Medical Devices\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We\u00a0 are\u00a0 pleased\u00a0\u00a0 to\u00a0 inform\u00a0 you\u00a0 that\u00a0 SBI\u00a0 Pharmaceuticals\u00a0\u00a0 Co.,\u00a0 Ltd.\u00a0 (Head\u00a0\u00a0 office:\u00a0 Minato-ku,\u00a0\u00a0 Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that it [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130920\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3297 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.08.30 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Submits a Phase-2 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. (TOKYO: 8473 \/ Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereinafter \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted a clinical trial application (CTA) to the [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20130830\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3298 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.08.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement\u2014the new drug \u201cALAGLIO\u00ae Internal Medicine 1.5g\u201d, an Orally-administered in vivo Diagnostic for Malignant Glioma, is Listed on the NHI Drug Price List\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinicacid (5-ALA) (*), announces that the in [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130827\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3299 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.08.26 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice Regarding Conclusion of Basic Agreement with King Hamad University Hospital in Bahrain on Clinical Study of 5 a minolevulinic a cid\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), has entered into [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130826\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3301 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.03.25 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Obtains Manufacture and Marketing Approval for Orally-administered in vivo Diagnostic Agent \u201cALAGLIO\u00ae\u201d for Malignant Glioma  \u2014 Japan\u2019s First Orally-administered Fluorescence Diagnostic Agent for Use in the Surgical  Resection of Brain Tumor\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (\u201c5-ALA\u201d), has obtained [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130325\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3310 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.03.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tJoint Clinical Research on Diabetes with Arabian Gulf University in Bahrain\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130321a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3309 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.03.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tBasic Agreement Reached with the Bahrain Development Bank for  Promoting 5-ALA Business in Bahrain\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached a [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20130321b\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3308 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.03.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on the Establishment of Joint Venture Company with Dawani Group Holding, a Major Corporate Group in Bahrain\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130321c\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3306 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.03.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tMemorandum of Understanding between Mumtalakat, the Sovereign Wealth Fund of  Bahrain, and SBI Pharmaceuticals Co., Ltd.  to Cooperate in the 5-ALA Business in Bahrain Focusing on the Pharmaceuticals Industry\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., has entered into a memorandum of understanding with Bahrain Mumtalakat Holding Company B.S.C. (c) (Head office: Manama, Bahrain; Chief [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130321d\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3304 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.03.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAgreement to Collaborate Reached with the Royal College of Surgeons in Ireland &#8211; Medical University of Bahrain for Starting Clinical Studies\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached an [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130321e\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3311 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.02.07 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on the Establishment of Joint Venture Company with Dawani Group Holding, Bahrain&#8217;s Major Corporate Group for Sales of 5-ALA Products\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has reached a [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130207\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3312 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.01.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Announces Conclusion of Basic Agreement to Start Clinical Research on Diabetes with Arabian Gulf University in Bahrain\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) announces that it has concluded a Basic Agreement to begin clinical research on diabetes in Bahrain with the Arabian Gulf University (AGU). <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20130121\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3313 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.01.16 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on the Press Release Published by the Bahrain Economic Development Board\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, cosmetics and health foods using 5-aminolevulinic acid (5-ALA) officially acquired a permit of opening a representative office on October 9, 2012, as announced in [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20130116\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3314 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2013.01.07 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Submits a Phase-1 Clinical Trial IND to U.S. FDA for a Drug to Treat Cancer Chemotherapy-induced Anemia\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. (TOKYO: 8473 \/ Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted an Investigational New Drug Application (IND) to the [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20130107\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3315 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.10.30 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20121030\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3316 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.10.11 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Obtains the Product License of Healthy Supplement from the Dubai Authority\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc. that conducts research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) announced that SBI Pharmaceuticals obtained the Product License of healthy supplement on [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20121011\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3317 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.10.10 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Opens a Representative Office in Bahrain\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, cosmetics and health foods using 5-aminolevulinic acid (5-ALA), opens a representative office in Manama, the capital of Bahrain. As announced in the press release [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20121010\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3318 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.09.20 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on the Appointment of a New Executive Officer\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), a subsidiary of SBI Holdings, Inc., is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new executive officer was appointed effective September [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20120920\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3319 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.08.01 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on the Appointment of a New Director\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d), an affiliate company of SBI Holdings, Inc. , is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new director was elected and [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20120801\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3320 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.07.06 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on application for marketing approval of in vivo diagnostic agent for malignant glioma in Japan\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. (TOKYO: 8473 \/ Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d) ,affiliate company of SBI Holdings, Inc. ,is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals and Nobelpharma [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20120706\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3322 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.06.26 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on Publication by Univ. of Hawaii of Paper on 5-ALA in Electronic Edition of U.S. Science Journal Clinical and Translational Science  Publication of the results of clinical studies on the relationship between 5-ALA and glucose levels\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Holdings, Inc. (\u201cSBIH\u201d) conducts research and development on cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (5-ALA) at its subsidiary SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative: Yoshitaka Kitao; \u201cSBI Pharmaceuticals\u201d). In relation to this, The University of Hawaii at Manoa Group has recently published [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20120626\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3326 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.04.24 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> Tokyo, April 24, 2012\uff0dSBI Pharmaceuticals Co., Ltd., announced that they had obtained Marketing Authorization of their products containing 5-ALA (*1) from The Kingdom of Bahrain Ministry of Health. SBI Pharmaceuticals signed a Memorandum of Understanding with the Government of The Kingdom of Bahrain for intensive collaboration of R&amp;D and distribution of 5-ALA in Bahrain and [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20120424\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3327 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.04.13 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on Agreement with Bahrain Government for the Promotion of the 5-ALA Business\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. (TOKYO: 8473 \/ Hong Kong: 6488) It is hereby notified that SBI Pharmaceuticals Co., Ltd., the SBI Holdings, Inc. subsidiary engaged in the research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA) (*1) (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereafter called \u201cSBI Pharmaceuticals\u201d) reached [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20120413\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3328 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2012.02.29 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tNotice on SBI ALApromo\u2019s Obtainment of First-class Marketing Authorization and Restructuring of ALA-related Business\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. (TOKYO: 8473 \/ Hong Kong: 6488) SBI ALApromo Co., Ltd., (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc., that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, hereby announces that it has obtained First-class Marketing Authorization [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20120229\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3332 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.28 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical  Oncology (1) <BR> &#8211; Success in diagnosis of peritoneal dissemination using ALA &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has succeeded in the detection of peritoneal dissemination of gastric cancer using ALA in [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20111028a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3329 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.28 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology (2) <BR> &#8211; Success in diagnosis of peritoneal dissemination and lymph node metastasis using ALA &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has succeeded in the detection of peritoneal dissemination of gastric cancer and lymph node [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20111028b\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3336 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting (2) <BR> &#8211; Finding of ALA\u2019s effect of enhancing hyperthermia therapy &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. which conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has discovered that ALA has the effect of enhancing hyperthermia therapy, in joint research [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20111005b\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3334 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.21 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine <BR> &#8211; Discovery of ALA\u2019s inhibitory effect on inflammatory cytokine production &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has discovered in joint research with Nihon University that ALA has the effect of [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20111021\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3337 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.05 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tThe study Results of ALA Presented Japanese Cancer Association, 70th Annual Meeting (1) <BR> &#8211; Finding of ALA\u2019s life-prolonging effect in mice with cancer &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has discovered that administration of ALA had the effect of controlling debilitation of cancer-bearing [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20111005a\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3335 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.05 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting (3) <BR> &#8211; Identification of sensitivity determinant in photodynamic therapy using ALA &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has identified a factor that determines sensitivity to photodynamic therapy using ALA, with Tokyo [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20111021c\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-27 post-3338 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">Information<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.10.03 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting. <BR> &#8211; Findings of ALA\u2019s growth inhibiting effect against P. falciparum malaria parasite growth &#8211;\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has found that ALA, a natural amino acid, has a growth inhibiting effect on [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/information\/20111003\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3341 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2011.03.18 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of publication of ALA research in International Immunopharmacology\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA) is pleased to announce that its research paper on the diagnosis and treatment [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20110318\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3342 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2010.11.30 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of orphan drug designation granted to orally active IN VIVO diagnostic agent for malignant glioma\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI ALApromo Co., Ltd. Nobelpharma Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA) *1 and Nobelpharma Co., Ltd. (head office: [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20101030\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3339 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2010.05.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of initiation of Phase III clinical study of orally active IN VIVO diagnostic agent for malignant glioma\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI ALApromo Co., Ltd. Nobelpharma Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA)*1, has reached agreement in principle with Nobelpharma [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20100527\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3343 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2010.04.01 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tAnnouncement of appointment of new executive officer\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA)*1, is pleased to announce the appointment of Motowo Nakajima as [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20100401\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3344 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2009.06.05 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tJoint Venture Formed with German Manufacturer medac to Pursue Pharmaceutical Development in Europe\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI ALApromo Co., Ltd. (Head office: Minato-ku, Tokyo; \u201cSBI ALApromo\u201d), a subsidiary of SBI Holdings, Inc. that researches, develops and markets cosmetics, health foods, and medicines using 5-aminolevulinic acid (ALA), and medac GmbH (Head office: Wedel, Germany; \u201cmedac\u201d), have signed an agreement on forming a joint venture company aimed at joint development of medicines in Europe. <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20090605\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3345 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2008.05.27 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tBiotechnology Joint Venture Agreement Signed between SBI Holdings and Cosmo Oil\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. COSMO OIL Co., Ltd. SBI Holdings, Inc. (Head office: Roppongi, Minato-ku, Tokyo; Representative: Yoshitaka Kitao; &#8220;SBI Holdings&#8221;) and Cosmo Oil Co., Ltd. (Head office: Shibaura, Minato-ku, Tokyo; Representative: Yaichi Kimura; &#8220;Cosmo Oil&#8221;) have signed today a joint venture agreement for the purpose of jointly developing &#8220;5-aminolevulinic acid (5-ALA),&#8221; a type of amino [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20080527\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<article class=\"elementor-portfolio-item elementor-post elementor-filter-28 post-3346 news type-news status-publish hentry\">\r\n      <div class=\"elementor-post\">\r\n\t\t\t<!-- <a class=\"elementor-post__thumbnail__link\" href=\"\"> -->\r\n\t\t\t\t<div class=\"elementor-portfolio-item__tags\">\r\n\t\t\t\t\t\t<span class=\"elementor-portfolio-item__tags__tag\">News<\/span>\t\t<\/div>\r\n\t\t    <div class=\"elementor-portfolio-item__date\"> 2008.04.24 <\/div>\r\n    \t\t<h3 class=\"elementor-portfolio-item__title\">\r\n\t\tSBI ALApromo Co., Ltd. Founded to Pursue New Business in the Biotechnology\t\t<\/h3>\r\n\t\t    <div class=\"elementor-portfolio-item__excerpt\"> SBI Holdings, Inc. SBI Holdings, Inc. (&#8220;the Company&#8221;) has founded SBI ALApromo Co., Ltd. (\u201cSBI ALApromo\u201d), a preparatory company that develops and markets medicines, cosmetics, and health food containing amino acid &#8220;5-aminolevulinic acid&#8221; (5-ALA) as an active ingredient. &#8220;5-ALA&#8221; is a natural amino acid that might appear 3.6 billion years ago and some foods such [&hellip;] <\/div>\r\n    \t\t<a href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/news-en\/20080424\/\" class=\"elementor-portfolio-item__readmore elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\r\n\t\t\t\t\t\t<span class=\"elementor-button-icon elementor-align-icon-right\">\r\n\t\t\t\t<i aria-hidden=\"true\" class=\"sbiicon- sbi-icon-sbi-arrow-cta\"><\/i>\t\t\t<\/span>\r\n\t\t\t\t\t\t<span class=\"elementor-button-text\">See more <\/span>\r\n\t\t<\/span>\r\n\t\t\t\t\t<\/a>\r\n   \r\n    \t\t<!-- <\/a> -->\r\n    <\/div>\r\n\t\t<\/article>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/p><\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-9e3b10a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9e3b10a\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b5c9990\" data-id=\"b5c9990\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2420ac1 elementor-widget elementor-widget-spacer\" data-id=\"2420ac1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>2026 2025 2024 2023 2022 2021 Before 2020 2026 2025 Category All Information News News 2025.11.21 Notice of Initiation and First Patient Enrollment in Phase III Study in Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer\u3000(ASTROPIC study) SBI Pharmaceuticals Co., Ltd., announces initiation of Phase III clinical study (ASTROPIC study) and first patient enrollment evaluating [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-1893","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SBI Pharma | News Release | Bladder Cancer Treatment | ALA<\/title>\n<meta name=\"description\" content=\"See the latest news on SBI Pharmaceuticals and topics around bladder cancer. We are specializing in the application of 5-ALA (5-aminolevulinic acid).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sbipharma.co.jp\/en\/news\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SBI Pharma | News Release | Bladder Cancer Treatment | ALA\" \/>\n<meta property=\"og:description\" content=\"See the latest news on SBI Pharmaceuticals and topics around bladder cancer. We are specializing in the application of 5-ALA (5-aminolevulinic acid).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sbipharma.co.jp\/en\/news\/\" \/>\n<meta property=\"og:site_name\" content=\"SBI Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T06:37:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sbipharma.co.jp\/wp-content\/uploads\/2020\/02\/SBI_HP-Image1_A_1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"550\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/news\\\/\",\"url\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/news\\\/\",\"name\":\"SBI Pharma | News Release | Bladder Cancer Treatment | ALA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/#website\"},\"datePublished\":\"2020-03-04T03:59:24+00:00\",\"dateModified\":\"2026-01-19T06:37:45+00:00\",\"description\":\"See the latest news on SBI Pharmaceuticals and topics around bladder cancer. We are specializing in the application of 5-ALA (5-aminolevulinic acid).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/news\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/news\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/news\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/\",\"name\":\"SBI Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/#organization\",\"name\":\"SBI Pharma\",\"url\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/wp-content\\\/uploads\\\/2020\\\/02\\\/SBI_Logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/wp-content\\\/uploads\\\/2020\\\/02\\\/SBI_Logo.png\",\"width\":259,\"height\":68,\"caption\":\"SBI Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sbipharma.co.jp\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SBI Pharma | News Release | Bladder Cancer Treatment | ALA","description":"See the latest news on SBI Pharmaceuticals and topics around bladder cancer. We are specializing in the application of 5-ALA (5-aminolevulinic acid).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sbipharma.co.jp\/en\/news\/","og_locale":"en_US","og_type":"article","og_title":"SBI Pharma | News Release | Bladder Cancer Treatment | ALA","og_description":"See the latest news on SBI Pharmaceuticals and topics around bladder cancer. We are specializing in the application of 5-ALA (5-aminolevulinic acid).","og_url":"https:\/\/www.sbipharma.co.jp\/en\/news\/","og_site_name":"SBI Pharma","article_modified_time":"2026-01-19T06:37:45+00:00","og_image":[{"width":1280,"height":550,"url":"https:\/\/www.sbipharma.co.jp\/wp-content\/uploads\/2020\/02\/SBI_HP-Image1_A_1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sbipharma.co.jp\/en\/news\/","url":"https:\/\/www.sbipharma.co.jp\/en\/news\/","name":"SBI Pharma | News Release | Bladder Cancer Treatment | ALA","isPartOf":{"@id":"https:\/\/www.sbipharma.co.jp\/en\/#website"},"datePublished":"2020-03-04T03:59:24+00:00","dateModified":"2026-01-19T06:37:45+00:00","description":"See the latest news on SBI Pharmaceuticals and topics around bladder cancer. We are specializing in the application of 5-ALA (5-aminolevulinic acid).","breadcrumb":{"@id":"https:\/\/www.sbipharma.co.jp\/en\/news\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sbipharma.co.jp\/en\/news\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sbipharma.co.jp\/en\/news\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/www.sbipharma.co.jp\/en\/"},{"@type":"ListItem","position":2,"name":"News"}]},{"@type":"WebSite","@id":"https:\/\/www.sbipharma.co.jp\/en\/#website","url":"https:\/\/www.sbipharma.co.jp\/en\/","name":"SBI Pharma","description":"","publisher":{"@id":"https:\/\/www.sbipharma.co.jp\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sbipharma.co.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sbipharma.co.jp\/en\/#organization","name":"SBI Pharma","url":"https:\/\/www.sbipharma.co.jp\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sbipharma.co.jp\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.sbipharma.co.jp\/wp-content\/uploads\/2020\/02\/SBI_Logo.png","contentUrl":"https:\/\/www.sbipharma.co.jp\/wp-content\/uploads\/2020\/02\/SBI_Logo.png","width":259,"height":68,"caption":"SBI Pharma"},"image":{"@id":"https:\/\/www.sbipharma.co.jp\/en\/#\/schema\/logo\/image\/"}}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Netwise","author_link":"https:\/\/www.sbipharma.co.jp\/en\/author\/admin_netwise\/"},"uagb_comment_info":0,"uagb_excerpt":"2026 2025 2024 2023 2022 2021 Before 2020 2026 2025 Category All Information News News 2025.11.21 Notice of Initiation and First Patient Enrollment in Phase III Study in Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer\u3000(ASTROPIC study) SBI Pharmaceuticals Co., Ltd., announces initiation of Phase III clinical study (ASTROPIC study) and first patient enrollment evaluating&hellip;","_links":{"self":[{"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/pages\/1893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/comments?post=1893"}],"version-history":[{"count":0,"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/pages\/1893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sbipharma.co.jp\/en\/wp-json\/wp\/v2\/media?parent=1893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}